Impact of Overlapping Heterogeneous Versus Homogeneous Drug-Eluting Stents on Clinical Outcomes: Should They Be Identical?
6 affiliations
- 1Department of Cardiology, Ankara University School of Medicine, 06230 Ankara, Türkiye
- 2Department of Cardiology, Simav State Hospital, 43500 Kütahya, Türkiye
- 3Department of Cardiology, İzmir Tepecik Training and Research Hospital, 35020 İzmir, Türkiye
- 4Department of Cardiology, Yıldırım Beyazıt University Yenimahalle Training and Research Hospital, 06370 Ankara, Türkiye
- 5Department of Cardiology, TOBB ETÜ Hospital, 06560 Ankara, Türkiye
- 6Department of Cardiology, Kırıkkale State Hospital, 06230 Kırıkkale, Türkiye
Abstract
Background: Stent overlapping serves as a crucial strategy in achieving complete coverage of diffuse coronary artery lesions, plaque shifts, and edge dissections. Objectives: We aimed to evaluate the long-term clinical outcomes of overlapping heterogeneous drug-eluting stents (DES) in comparison to homogeneous DES. Methods: A total of 421 patients treated with overlapping DES were included in the study. The study patients were stratified into two groups according to the type of overlap: homogeneous (same antiproliferative drug and stent platform) and heterogeneous (different drug and/or platform). The primary endpoint was a device-oriented composite of cardiac death, target-vessel myocardial infarction and target lesion revascularization; a broader composite of all-cause death, any repeat revascularization, stent thrombosis, in-stent restenosis and cerebrovascular events (MACE) and its components were secondary endpoints. Propensity-score analysis with inverse probability of treatment weighting (IPTW) was used to account for treatment-selection bias. Results: The device-oriented composite endpoint occurred in 9.3% and 7.1% (p = 0.60), and MACE in 17.6% and 14.7% (p = 0.56) of patients with homogeneous and heterogeneous DES, respectively, with no significant difference in any individual component. After IPTW adjustment, heterogeneous overlap was not associated with an increased risk of MACE (odds ratio: 0.45, 95% confidence interval: 0.23–0.86) or of the device-oriented composite endpoint (0.52, 0.22–1.23). In a multivariable model with clinically prespecified covariates, lower left ventricular ejection fraction and greater total stent length, but not HbA1c, were independently associated with MACE. Conclusions: In this retrospective cohort, overlapping heterogeneous DES was not associated with an increased risk of adverse events compared with homogeneous DES, including in patients presenting with acute coronary syndromes; however, the modest sample size and the low number of events preclude conclusions of equivalence, and clinically relevant differences cannot be excluded.
Related
- CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant
- Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
- Divergent PICU lengths of stay despite identical phoenix sepsis scores: heterogeneity in pediatric sepsis outcomes according to system involvement profiles
- Diagnostic Yield and Clinical Phenotype in a Lithuanian Familial Hypercholesterolemia Cohort with Heterogeneous Sequencing Platforms
- Spatially-resolved multimodal profiling identifies functionally-heterogeneous cancer-associated fibroblasts associated with poor radiotherapy outcomes in muscle-invasive bladder cancer.
BibTeX
@article{esenboga2026impact,
title = {{Impact of Overlapping Heterogeneous Versus Homogeneous Drug-Eluting Stents on Clinical Outcomes: Should They Be Identical?}},
author = {Kerim Esenboğa and Müge Akbulut and Bilge Nazar Ateş and Halil Gülyiğit and Emre Özerdem and Yakup Yunus Yamantürk and Şeyhmus Atan and Eralp Tutar},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218342},
url = {https://www.mdpi.com/2077-0383/15/21/8342},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Impact of Overlapping Heterogeneous Versus Homogeneous Drug-Eluting Stents on Clinical Outcomes: Should They Be Identical?
AU - Kerim Esenboğa
AU - Müge Akbulut
AU - Bilge Nazar Ateş
AU - Halil Gülyiğit
AU - Emre Özerdem
AU - Yakup Yunus Yamantürk
AU - Şeyhmus Atan
AU - Eralp Tutar
PY - 2026
DA - 2026/10/26
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218342
UR - https://www.mdpi.com/2077-0383/15/21/8342
AB - Background: Stent overlapping serves as a crucial strategy in achieving complete coverage of diffuse coronary artery lesions, plaque shifts, and edge dissections. Objectives: We aimed to evaluate the long-term clinical outcomes of overlapping heterogeneous drug-eluting stents (DES) in comparison to homogeneous DES. Methods: A total of 421 patients treated with overlapping DES were included in the study. The study patients were stratified into two groups according to the type of overlap: homogeneous (same antiproliferative drug and stent platform) and heterogeneous (different drug and/or platform). The primary endpoint was a device-oriented composite of cardiac death, target-vessel myocardial infarction and target lesion revascularization; a broader composite of all-cause death, any repeat revascularization, stent thrombosis, in-stent restenosis and cerebrovascular events (MACE) and its components were secondary endpoints. Propensity-score analysis with inverse probability of treatment weighting (IPTW) was used to account for treatment-selection bias. Results: The device-oriented composite endpoint occurred in 9.3% and 7.1% (p = 0.60), and MACE in 17.6% and 14.7% (p = 0.56) of patients with homogeneous and heterogeneous DES, respectively, with no significant difference in any individual component. After IPTW adjustment, heterogeneous overlap was not associated with an increased risk of MACE (odds ratio: 0.45, 95% confidence interval: 0.23–0.86) or of the device-oriented composite endpoint (0.52, 0.22–1.23). In a multivariable model with clinically prespecified covariates, lower left ventricular ejection fraction and greater total stent length, but not HbA1c, were independently associated with MACE. Conclusions: In this retrospective cohort, overlapping heterogeneous DES was not associated with an increased risk of adverse events compared with homogeneous DES, including in patients presenting with acute coronary syndromes; however, the modest sample size and the low number of events preclude conclusions of equivalence, and clinically relevant differences cannot be excluded.
SN - 2077-0383
ER -